BioClinica, Inc. to Present at the 11th Annual JMP Securities Research Conference in San Francisco on May 14, 2012

  BioClinica, Inc. to Present at the 11th Annual JMP Securities Research
  Conference in San Francisco on May 14, 2012

11th Annual JMP Securities Research Conference

Business Wire

NEWTOWN, Pa. -- April 24, 2012

BioClinica®, Inc. (NASDAQ: BIOC) today announced Mark L. Weinstein, President
and Chief Executive Officer will be presenting at the 11th Annual JMP
Securities Research Conference in San Francisco on Monday, May 14, 2012 at
4:00 p.m. PDT.

Mr. Weinstein will be discussing an overview of BioClinica, its business
strategy and financial performance.

The Company will provide a live webcast of the presentation. To access this
presentation, listeners should go to the following link, approximately 15
minutes prior to the event to register and download any necessary software:

             http://www.bioclinica.com/Investors/investor-events/

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated,
technology-enhanced clinical trial management solutions. BioClinica supports
pharmaceutical and medical device innovation with imaging core lab, internet
image transport, electronic data capture, interactive voice and web response,
clinical trial management and clinical supply chain design and optimization
solutions. BioClinica solutions maximize efficiency and manageability
throughout all phases of the clinical trial process. With over 20 years of
experience and more than 2,000 successful trials to date, BioClinica has
supported the clinical development of many new medicines from early phase
trials through final approval. BioClinica operates state-of-the-art,
regulatory-body-compliant imaging core labs on two continents, and supports
worldwide eClinical and data management services from offices in the United
States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking
statements” intended to qualify for the safe harbors from liability
established by the Private Securities Litigation Reform Act of 1995.In
particular, the Company’s statements regarding trends in the marketplace and
potential future results are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties, including, but not
limited to, the consummation and the successful integration of current and
proposed acquisitions, the timing of projects due to the variability in size,
scope and duration of projects, estimates and guidance made by management with
respect to the Company’s financial results, backlog, critical accounting
policies, regulatory delays, clinical study results which lead to reductions
or cancellations of projects, and other factors, including general economic
conditions and regulatory developments, not within the Company’s control.The
factors discussed herein and expressed from time to time in the Company’s
filings with the Securities and Exchange Commission could cause actual results
and developments to be materially different from those expressed in or implied
by such statements.The forward-looking statements are made only as of the date
of this press release and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events or
circumstance. You should review the Company’s filings, especially risk factors
contained in the Form 10-K and the recent Form 10-Q.

Contact:

BioClinica, Inc.
Jim Dorsey, 267-757-3040
or
Porter, LeVay & Rose, Inc.
Investors – Michael Porter
Financial Media - Bill Gordon
212-564-4700